Research

Clinical Trials
One of the hallmarks of Aptium Oncology\\\'s success in a rapidly evolving environment is its robust suite of research capabilities. Each cancer center in the Aptium Oncology network has capabilities to perform clinical trials in breast, leukemia, lung, lymphoma, sarcoma and other cancers.

For more information about an Aptium Oncology-affiliated cancer center\\\'s interest in opening a clinical trial, please contact Aptium Oncology\\\'s research department at (323) 966-3634.

World-class investigators and institutions
In addition, Aptium Oncology maintains a consortium of world-class investigators and institutions committed to advancing clinical and translational research in gastrointestinal malignancies through the Aptium Oncology GI Cancer Consortium (AGICC), and in myeloma through the Aptium Oncology Myloma Cancer Consortium (AMyC). Both consortia offer an innovative and focused research model that speeds decision-making by pharmaceutical sponsors on the development of drugs.

AGICC and AMyC work closely with several pharmaceutical and biotechnology companies in the country, and maintain a roster of nationally and internationally renowned researchers involved in the discovery and development of groundbreaking cancer therapies.

For more information, log on to www.agicc.org or www.ammyc.org or contact: Marti McKinley, Vice President of Clinical Research Programs, (323) 966-3599 or mmckinley@agicc.org.